Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 19/20 | 0.72 |
| ▸ | MAOB | P27338 | 9/20 | 0.72 |
| ▸ | MAOA | P21397 | 4/20 | 0.72 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.72 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.72 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.72 |
| ▸ | HTR1B | P28222 | 1/20 | 0.72 |
| ▸ | HTR2A | P28223 | 1/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL900350 | 0.98 | KDM1A (0.70) | KDM1AMAOBMAOACISD1KDM1B | |
| SCHEMBL900351 | 0.98 | KDM1A (0.70) | KDM1AMAOBMAOACISD1KDM1B | |
| SCHEMBL14880466 | 0.84 | KDM1A (0.91) | KDM1AMAOBMAOACISD1KDM1B | |
| SCHEMBL16407925 | 0.84 | KDM1A (0.91) | KDM1AMAOBMAOACISD1KDM1B | |
| SCHEMBL14880468 | 0.84 | KDM1A (0.91) | KDM1AMAOBMAOACISD1KDM1B | |
| SCHEMBL14880428 | 0.84 | KDM1A (1.00) | KDM1AMAOBMAOACISD1KDM1B | |
| Iadademstat SCHEMBL16010213 | 0.84 | KDM1A (1.00) | KDM1AMAOBMAOACISD1KDM1B | |
| SCHEMBL14880456 | 0.84 | KDM1A (1.00) | KDM1AMAOBMAOACISD1KDM1B | |
| Iadademstat SCHEMBL19409823 | 0.84 | KDM1A (1.00) | KDM1AMAOBMAOACISD1KDM1B | |
| SCHEMBL14880427 | 0.84 | KDM1A (1.00) | KDM1AMAOBMAOACISD1KDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3133059-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | Oryzon Genomics, S.A. (ES) | 2017-02-22 | — | — | EP | claimed |
| EP-2560947-B1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | ORYZON GENOMICS SA (ES) | 2016-10-12 | — | — | EP | claimed |
| US-20150368186-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | ORYZON GENOMICS S.A. | 2015-12-24 | — | — | US | claimed |
| US-20140213657-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | ORYZON GENOMICS S.A. (ES) | 2014-07-31 | — | — | US | claimed |
| US-8722743-B2 | Lysine specific demethylase-1 inhibitors and their use | ORYZON GENOMICS S.A. (ES) | 2014-05-13 | — | — | US | claimed |
| US-20130090386-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | ORYZON GENOMICS S.A. | 2013-04-11 | — | — | US | claimed |
| EP-2560947-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | Oryzon Genomics, S.A. (ES) | 2013-02-27 | — | — | EP | claimed |
| WO-2011131697-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | ORYZON GENOMICS S.A. (ES) | 2011-10-27 | — | — | WO | claimed |
| EP-3981395-A1 | LYSINE DEMETHYLASE INHIBITORS FOR MYELOPROLIFERATIVE DISORDERS | Oryzon Genomics, S.A. (ES) | 2022-04-13 | — | — | EP | disclosed |
| EP-2712315-B1 | LYSINE DEMETHYLASE INHIBITORS FOR MYELOPROLIFERATIVE DISORDERS | ORYZON GENOMICS SA (ES) | 2021-11-24 | — | — | EP | disclosed |
| US-10202330-B2 | Lysine specific demethylase-1 inhibitors and their use | ORYZON GENOMICS, SA (ES) | 2019-02-12 | — | — | US | disclosed |
| US-9908859-B2 | Lysine demethylase inhibitors for myeloproliferative disorders | ORYZON GENOMICS, S.A. (ES) | 2018-03-06 | — | — | US | disclosed |
| US-9790196-B2 | Lysine demethylase inhibitors for diseases and disorders associated with Flaviviridae | ORYZON GENOMICS S.A. (ES) | 2017-10-17 | — | — | US | disclosed |
| US-20170209432-A1 | LYSINE DEMETHYLASE INHIBITORS FOR MYELOPROLIFERATIVE OR LYMPHOPROLIFERATIVE DISEASES OR DISORDERS | ORYZON GENOMICS SA (ES) | 2017-07-27 | — | — | US | disclosed |
| WO-2012156531-A2 | LYSINE DEMETHYLASE INHIBITORS FOR INFLAMMATORY DISEASES OR CONDITIONS | ORYZON GENOMICS, S.A. (ES) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012107499-A1 | LYSINE DEMETHYLASE INHIBITORS FOR MYELOPROLIFERATIVE OR LYMPHOPROLIFERATIVE DISEASES OR DISORDERS | ORYZON GENOMICS S.A. (ES) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012107498-A1 | LYSINE DEMETHYLASE INHIBITORS FOR MYELOPROLIFERATIVE DISORDERS | ORYZON GENOMICS S.A. (ES) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012072713-A2 | LYSINE DEMETHYLASE INHIBITORS FOR DISEASES AND DISORDERS ASSOCIATED WITH FLAVIVIRIDAE | ORYZON GENOMICS, S.A. (ES) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012042042-A1 | SELECTIVE LSD1 AND DUAL LSD1/MAO-B INHIBITORS FOR MODULATING DISEASES ASSOCIATED WITH ALTERATIONS IN PROTEIN CONFORMATION | ORYZON GENOMICS S.A. (ES) | 2012-04-05 | — | — | WO | disclosed |
| WO-2011131697-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | ORYZON GENOMICS S.A. (ES) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368186-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | KDM1A, KDM1B, KDM3A | KDM1A 1/4885MAOB 227/4885MAOA 301/4885 |
| US-10202330-B2 | Lysine specific demethylase-1 inhibitors and their use | KDM1A, KDM1B, KDM3A | KDM1A 1/4885MAOB 219/4885MAOA 302/4885 |
| US-20170209432-A1 | LYSINE DEMETHYLASE INHIBITORS FOR MYELOPROLIFERATIVE OR LYMPHOPROLIFERATIVE DISEASES OR DISORDERS | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MAOB 1065/4885MAOA 1481/4885 |
| US-20130090386-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | KDM1A, KDM1B, KDM3A | KDM1A 1/4885MAOB 219/4885MAOA 302/4885 |
| US-20140213657-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | KDM1A, KDM1B, KDM3A | KDM1A 1/4885MAOB 244/4885MAOA 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.